Indian subsidiary of Merck Sharp and Dohme (MSD), a drug firm has decided to enter into voluntary licensing agreements for investigational oral antiviral drug candidate ‘molnupiravir’, it said on Tuesday.
The drug is being studied for the treatment of Covid-19 with Indian firms Sun Pharma, Cipla, Dr Reddy’s, Emcure Pharma and Hetero Labs.
Molnupiravir is currently being studied in a Phase 3 trial for treatment of non-hospitalized patients with confirmed Covid-19, MSD India said in a statement.
Uncovering the Molecular Secrets of Malaria’s Deadliest Strain: A New Research Project Malaria remains one…
Sunlight Can Cause Cancer: Prolonged exposure to sunlight and exposure to UV (ultraviolet) rays can…
https://youtu.be/mlBSCMO2NQg?si=UfC4C3WgtMZ9DhB4 Humans Are Swallowing Microplastics: A Hidden Environmental and Health Crisis In recent years, microplastics…
https://youtu.be/H_aiXVvX8Eg?si=vH4Arvq7pbpXERMF Obesity Drugs: A Comprehensive Guide to Weight Loss Solutions Obesity is one of the…
https://youtu.be/LZi8Jn0tAA8?si=bpMPudQxl1LUdgXN Cold Hands & Feet in Winter: Causes, Remedies, and Prevention Tips Winter can be…
Dysautonomia: The Silent Illness Impacting Millions of People Worldwide Dysautonomia is an umbrella term used…